Compare GSHD & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSHD | INBX |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 999.7M |
| IPO Year | 2018 | 2024 |
| Metric | GSHD | INBX |
|---|---|---|
| Price | $40.68 | $132.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 3 |
| Target Price | $72.50 | ★ $150.00 |
| AVG Volume (30 Days) | 381.2K | ★ 486.3K |
| Earning Date | 04-22-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $365,304,000.00 | $1,300,000.00 |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $18.53 | N/A |
| P/E Ratio | $40.72 | ★ N/A |
| Revenue Growth | 16.15 | ★ 550.00 |
| 52 Week Low | $39.64 | $12.80 |
| 52 Week High | $114.76 | $155.29 |
| Indicator | GSHD | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 66.58 |
| Support Level | N/A | $69.30 |
| Resistance Level | $46.40 | $155.29 |
| Average True Range (ATR) | 2.86 | 13.75 |
| MACD | -0.51 | 0.62 |
| Stochastic Oscillator | 3.26 | 69.23 |
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.